Abionyx Pharma (XPAR:ABNX) Change In Receivables : €0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Abionyx Pharma Change In Receivables?

Abionyx Pharma's change in receivables for the quarter that ended in Dec. 2023 was €0.00 Mil. It means Abionyx Pharma's Accounts Receivable stayed the same from Jun. 2023 to Dec. 2023 .

Abionyx Pharma's change in receivables for the fiscal year that ended in Dec. 2023 was €0.38 Mil. It means Abionyx Pharma's Accounts Receivable declined by €0.38 Mil from Dec. 2022 to Dec. 2023 .

Abionyx Pharma's Accounts Receivable for the quarter that ended in Dec. 2023 was €0.73 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Abionyx Pharma's Days Sales Outstanding for the six months ended in Dec. 2023 was 52.89.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Abionyx Pharma's liquidation value for the six months ended in Dec. 2023 was €-2.15 Mil.

Abionyx Pharma Change In Receivables Historical Data

The historical data trend for Abionyx Pharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abionyx Pharma Change In Receivables Chart

Abionyx Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-0.10

0.04

0.38

Abionyx Pharma Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Abionyx Pharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

Abionyx Pharma (XPAR:ABNX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Abionyx Pharma's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.728	/	2.512	*	91
=	52.89

2. In Ben Graham's calculation of liquidation value, Abionyx Pharma's accounts receivable are only considered to be worth 75% of book value:

Abionyx Pharma's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	4.104	-	6.912	+	0.75 * 0.728	+	0.5 * 0.221
=	-2.15

Abionyx Pharma Change In Receivables Related Terms

Thank you for viewing the detailed overview of Abionyx Pharma's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Abionyx Pharma (XPAR:ABNX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abionyx Pharma (XPAR:ABNX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

609:Germany

Address

33-43 Avenue Georges Pompidou-Bat D2, Balma, FRA, 31130

Website

https://www.abionyx.com

Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.

Abionyx Pharma (XPAR:ABNX) Headlines

No Headlines